Skip to main content

Advertisement

SpringerLink
Log in

Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Clinical efficacy of aggressive end-of-life (EOL) chemotherapy remains unclear.

Method

Medical records of patients with advanced cancer between August 2011 and August 2016 were retrospectively analyzed. The primary endpoint was to identify prognostic factors at the last administration of chemotherapy. The secondary endpoint was to analyze the relationship between EOL symptoms and EOL treatment details.

Results

Among 300 evaluated patients, the number of patients who died within 14 and 30 days from the last administration of chemotherapy were 16 (5.3%) and 50 (16.7%), respectively. Multivariate analysis revealed that ECOG-PS (OR 3.698, p < 0.001) and GPS2 (OR 3.791, p = 0.028) were significant prognostic factors. The MST of patients with both PS 2–4 and GPS2 (+) was 38 days, while that in patients with both PS 0–1 and GPS2 (−) was 134.5 days. The prevalence rate of nausea and vomiting (25.0%) and the mean hydration volume (0.50 L/day) in patients who died within 30 days from the chemotherapy was significantly higher than others (7.4%) (0.20 L/day).

Conclusion

ECOG-PS and GPS were significant prognostic factors for aggressive EOL chemotherapy. Information on these factors may aid clinical decision-making in terms of risk–benefit balance, particularly in patients with poor prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Earle CC, Neville BA, Lndrum MB et al (2004) Trends in aggressiveness of cancer care near the end of life. J Clin Oncol 22:315–321

    Article  PubMed  Google Scholar 

  2. Nappa U, Lindqvist O, Rasmussen BA et al (2011) Palliative chemotherapy during the last month of life. Ann Oncol 22:2375–2380

    Article  PubMed  CAS  Google Scholar 

  3. Braga S, Rute Fonseca AM, Moreira A et al (2007) The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis. Pscho-Oncology 16:863–868

    Article  Google Scholar 

  4. Barbera L (2006) Indicators of poor quality end-of-life cancer care in Ontario. J Palliat Care 22:12–17

    Article  PubMed  Google Scholar 

  5. Hanny A, Sonja H, Georg B (2014) Chemotherapy near the end of life: a retrospective single-centere analysis of patients’ charts. BMC Palliat Care 13:26

    Article  Google Scholar 

  6. Kao S, Shafig J, Adams D (2009) Use of chemotherapy at end of life in oncology patients. Ann Oncol 20:1555–1559

    Article  PubMed  CAS  Google Scholar 

  7. Petra G, Aynharan S, Theresas T et al (2015) Variations in intensity of end-of-life cancer therapy by cancer type at a Canadian tertiary cancer centre between 2003 and 2010. Support Care Cancer 23(10):3059–67

    Article  Google Scholar 

  8. Forrest LM, McMillan DC, McArdle CS et al (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89:1028–1030

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Inoue SK, van Dyck CH, Alessi CA et al (1990) Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 113:941–948

    Article  Google Scholar 

  10. Morita T, Bito S, Kurihara Y et al (2005) Development of a clinical guideline for palliative sedation therapy using the Delphi method. J Palliat Med 8:716–729

    Article  PubMed  Google Scholar 

  11. Prigerson HG, Bao Y, Shah M et al (2015) Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol 1(6):778–784

    Article  PubMed  PubMed Central  Google Scholar 

  12. Nozoe T, Ninomiya M, Maeda T et al (2010) Prognostic nutritional index: a tool to predict the biological aggressivenesss of gastric carcinoma. Surg Today 40:440–443

    Article  PubMed  Google Scholar 

  13. Maeda K, Shibutani M, Otani H et al (2014) Low nutritional prognostic index correlates with poor survival in patients with stage IV colorectal cancer following palliative resection of the primary tumor. Eorld J Surg 38:1217–1222

    Google Scholar 

  14. Kanda M, Fujii T, Kodera Y et al (2011) Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 98:268–274

    Article  PubMed  CAS  Google Scholar 

  15. Masaichi O, Naoshi K, Go M et al (2015) Glasgow prognostic score as a prognostic clinical marker in T4 esophageal squamous cell carcinoma. Anticancer Res 35:4897–4902

    Google Scholar 

  16. Okuno T, Wakabayashi M, Kato K et al (2017) Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). Int J Clin Oncol 22(6):1042–1049

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Hiramoto S, Kato K, Boku N (2018) A retrospective analysis of 5-fluorouracil plus cisplatin as first line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. Int J Clin Oncol 23(3):466–472

    Article  PubMed  CAS  Google Scholar 

  18. Inoue A, Kobayashi K, Usui K et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27(9):1394–1400

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Oncology and Palliative Medicine, Mitsubishi Kyoto Hospital, Kyoto, Japan

    Shuji Hiramoto, Tetsuo Hori, Ayako Kikuchi & Akira Yoshioka

  2. Department of Nursing, Mukogawa Woman’s University, Nishinomiya, Japan

    Tomoko Tamaki

  3. The Institute of Statistical Mathematics, Tachikawa, Japan

    Kengo Nagashima

  4. Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan

    Akira Inoue

Authors
  1. Shuji Hiramoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomoko Tamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kengo Nagashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tetsuo Hori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ayako Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akira Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akira Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuji Hiramoto.

Ethics declarations

Conflict of interest

All the authors have approved the submission of this manuscript to your journal. There are no conflicts of interest to declare.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PPTX 54 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hiramoto, S., Tamaki, T., Nagashima, K. et al. Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer. Int J Clin Oncol 24, 454–459 (2019). https://doi.org/10.1007/s10147-018-1363-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-018-1363-7

Keywords

Search

Navigation